Suppr超能文献

与使用酸抑制药物相关的结直肠癌风险。

Colorectal cancer risk in relation to use of acid suppressive medications.

机构信息

Group Health Center for Health Studies, Seattle, WA 98101-1448, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):540-4. doi: 10.1002/pds.1749.

Abstract

PURPOSE

Acid suppressants are commonly prescribed medications. Laboratory studies suggest a mechanism by which they could increase colorectal cancer (CRC) risk. A few epidemiologic studies have investigated acid suppressant use and CRC risk; none has documented an overall association. We sought to investigate whether acid suppressants are associated with CRC risk.

METHODS

We conducted a case-control study among members of an integrated healthcare delivery system in Washington State. Cases (N = 641) were diagnosed with CRC between 2000 and 2003; controls (N = 641) were randomly selected from enrollees and matched to cases on age, sex, and length of enrollment. We used conditional logistic regression to estimate the odds ratios (ORs) and 95% confidence intervals (CI) for CRC associated with the use of any acid suppressive medication, proton pump inhibitors (PPIs) only, histamine receptor antagonists (H2 blockers) only, or both PPIs and H2 blockers in relation to the use of neither PPIs nor H2 blockers.

RESULTS

Use of PPIs exclusively was modestly associated with an increased risk of CRC, however this finding was consistent with chance and based on a small number of patients exposed (OR = 1.7; 95%CI = 0.8, 4.0). H2 blocker use alone was not related to CRC risk (OR = 0.8; 95%CI = 0.6, 1.1).

CONCLUSIONS

PPI use may be modestly associated with CRC risk; further research should be conducted in populations with long-term PPI use.

摘要

目的

抑酸剂是常用的处方药物。实验室研究表明其可能具有增加结直肠癌(CRC)风险的作用机制。一些流行病学研究调查了抑酸剂的使用与 CRC 风险之间的关系,但均未证明存在总体相关性。我们旨在研究抑酸剂是否与 CRC 风险相关。

方法

我们在华盛顿州一个综合医疗服务系统的成员中进行了一项病例对照研究。病例(N=641)于 2000 年至 2003 年间被诊断为 CRC;对照组(N=641)从参保者中随机选择,并按年龄、性别和参保时间与病例相匹配。我们使用条件 logistic 回归估计了使用任何抑酸药物、仅质子泵抑制剂(PPIs)、仅组胺受体拮抗剂(H2 阻滞剂)或 PPI 和 H2 阻滞剂两者联合与既不使用 PPI 也不使用 H2 阻滞剂相关的 CRC 的比值比(OR)和 95%置信区间(CI)。

结果

仅使用 PPI 与 CRC 风险适度增加相关,但这一发现与偶然因素一致,且基于暴露的患者数量较少(OR=1.7;95%CI=0.8, 4.0)。单独使用 H2 阻滞剂与 CRC 风险无关(OR=0.8;95%CI=0.6, 1.1)。

结论

PPI 使用可能与 CRC 风险适度相关;应在长期使用 PPI 的人群中进一步开展研究。

相似文献

1
Colorectal cancer risk in relation to use of acid suppressive medications.
Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):540-4. doi: 10.1002/pds.1749.
3
Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
Br J Cancer. 2020 Sep;123(5):844-851. doi: 10.1038/s41416-020-0939-y. Epub 2020 Jun 16.
4
Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Gastroenterology. 2007 Sep;133(3):755-60. doi: 10.1053/j.gastro.2007.06.014. Epub 2007 Jun 20.
5
Use of proton pump inhibitors and risk of pancreatic cancer.
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):926-930. doi: 10.1002/pds.4576. Epub 2018 Jun 20.
9
Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Osteoporos Int. 2015 Oct;26(10):2501-7. doi: 10.1007/s00198-015-3168-0. Epub 2015 May 19.
10
Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study.
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101397. doi: 10.1016/j.clinre.2020.02.017. Epub 2020 Mar 27.

引用本文的文献

1
Sex Differences in Colorectal Cancer: Epidemiology, Risk Factors, and Clinical Outcomes.
J Clin Med. 2025 Aug 6;14(15):5539. doi: 10.3390/jcm14155539.
2
Proton pump inhibitors and all-cause mortality in colorectal cancer.
Sci Rep. 2025 Jul 1;15(1):21315. doi: 10.1038/s41598-025-05570-4.
4
Unveiling the Latest Breakthroughs: A Comprehensive Review of the Therapeutic Activity and Safety Profile of .
Curr Drug Saf. 2024;19(4):407-416. doi: 10.2174/0115748863274759231221093309.
7
Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.
Front Pharmacol. 2023 Mar 16;14:1129948. doi: 10.3389/fphar.2023.1129948. eCollection 2023.
8
Oral contraceptives and colorectal cancer risk - A meta-analysis and systematic review.
Ann Med Surg (Lond). 2022 Oct 3;83:104254. doi: 10.1016/j.amsu.2022.104254. eCollection 2022 Nov.
10
Proton pump inhibitors and colorectal cancer: A systematic review.
World J Gastroenterol. 2021 Nov 28;27(44):7716-7733. doi: 10.3748/wjg.v27.i44.7716.

本文引用的文献

1
Cardiovascular medication use and risk for colorectal cancer.
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3076-80. doi: 10.1158/1055-9965.EPI-08-0095. Epub 2008 Oct 28.
2
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1858-61. doi: 10.1158/1055-9965.EPI-07-0710.
3
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1852-7. doi: 10.1158/1055-9965.EPI-08-0167.
4
Statin use and prostate cancer risk in a large population-based setting.
Cancer Causes Control. 2008 Sep;19(7):767-74. doi: 10.1007/s10552-008-9139-4. Epub 2008 Mar 6.
5
Proton pump inhibitors and the risk of colorectal cancer.
Am J Gastroenterol. 2008 Apr;103(4):966-73. doi: 10.1111/j.1572-0241.2007.01665.x. Epub 2007 Dec 5.
6
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Gastroenterology. 2007 Sep;133(3):748-54. doi: 10.1053/j.gastro.2007.06.022. Epub 2007 Jun 20.
7
Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Gastroenterology. 2007 Sep;133(3):755-60. doi: 10.1053/j.gastro.2007.06.014. Epub 2007 Jun 20.
9
The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.
Am J Gastroenterol. 2007 May;102(5):942-50. doi: 10.1111/j.1572-0241.2007.01106.x. Epub 2007 Feb 21.
10
COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer.
Br J Cancer. 2002 Aug 27;87(5):574-9. doi: 10.1038/sj.bjc.6600495.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验